Doctors and patients report on new hair loss drug

NCT ID NCT07200128

Summary

This study looked back at survey data from US dermatologists and their adult patients with severe alopecia areata, a condition causing significant hair loss. It aimed to understand the real-world experiences of patients taking a medication called ritlecitinib and their doctors' satisfaction with it. The research analyzed how patients' hair loss severity changed over time while on the treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Pfizer

    New York, New York, 10001, United States

Conditions

Explore the condition pages connected to this study.